
Living Cell Technologies Limited – OTC:LVCLY
Living Cell Technologies Limited stock price today
Living Cell Technologies Limited stock price monthly change
Living Cell Technologies Limited stock price quarterly change
Living Cell Technologies Limited stock price yearly change
Living Cell Technologies Limited key metrics
Market Cap | 9.73M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | N/A |
Revenue | N/A |
EBITDA | -3.01M |
Income | -3.12M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeLiving Cell Technologies Limited stock price history
Living Cell Technologies Limited stock forecast
Living Cell Technologies Limited financial statements
Sep 2021 | 0 | -367.00K | |
---|---|---|---|
Dec 2021 | 0 | -734.00K | |
Jun 2022 | 3.40K | -1.22M | -35926.49% |
Jun 2023 | 42.01K | -801.13K | -1906.75% |
Dec 2021 | 4455821 | 377.73K | 8.48% |
---|---|---|---|
Sep 2022 | 3115902 | 382.76K | 12.28% |
Dec 2022 | 3115902 | 382.76K | 12.28% |
Jun 2023 | 4211959 | 449.85K | 10.68% |
Jun 2021 | -835.88K | 105.85K | -18.31K |
---|---|---|---|
Dec 2021 | -597.55K | 43.30K | 3.39M |
Jun 2022 | -1.44M | -3.80K | 1.29M |
Jun 2023 | -833.79K | -4.11M | 1.85M |
Living Cell Technologies Limited alternative data
Apr 2024 | 48 |
---|---|
May 2024 | 48 |
Jun 2024 | 48 |
Jul 2024 | 48 |
Living Cell Technologies Limited other data
-
What's the price of Living Cell Technologies Limited stock today?
One share of Living Cell Technologies Limited stock can currently be purchased for approximately $0.05.
-
When is Living Cell Technologies Limited's next earnings date?
Unfortunately, Living Cell Technologies Limited's (LVCLY) next earnings date is currently unknown.
-
Does Living Cell Technologies Limited pay dividends?
No, Living Cell Technologies Limited does not pay dividends.
-
How much money does Living Cell Technologies Limited make?
Living Cell Technologies Limited has a market capitalization of 9.73M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 1133.95% to 42.02K US dollars.
-
What is Living Cell Technologies Limited's stock symbol?
Living Cell Technologies Limited is traded on the OTC under the ticker symbol "LVCLY".
-
What is Living Cell Technologies Limited's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Living Cell Technologies Limited?
Shares of Living Cell Technologies Limited can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
When Living Cell Technologies Limited went public?
Living Cell Technologies Limited is publicly traded company for more then 18 years since IPO on 17 Jul 2007.
-
What is Living Cell Technologies Limited's official website?
The official website for Living Cell Technologies Limited is lctglobal.com.
-
Where are Living Cell Technologies Limited's headquarters?
Living Cell Technologies Limited is headquartered at 330 Collins Street, Melbourne, VIC.
-
How can i contact Living Cell Technologies Limited?
Living Cell Technologies Limited's mailing address is 330 Collins Street, Melbourne, VIC and company can be reached via phone at +61 3 8689 9997.
Living Cell Technologies Limited company profile:

Living Cell Technologies Limited
lctglobal.comOTC
0
Biotechnology
Healthcare
Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in Australia and New Zealand. It is developing NTCELL, an alginate-coated capsule, which is in phase IIb clinical trial for the treatment of Parkinson's disease. The company was founded in 1987 and is based in Sydney, Australia.
Melbourne, VIC 2000
:
ISIN: US53838R1077
: